Insulet Management
Management criteria checks 3/4
Insulet's CEO is Jim Hollingshead, appointed in Jun 2022, has a tenure of 1.75 years. total yearly compensation is $11.18M, comprised of 3.9% salary and 96.1% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth $2.41M. The average tenure of the management team and the board of directors is 3.8 years and 5.2 years respectively.
Key information
Jim Hollingshead
Chief executive officer
US$11.2m
Total compensation
CEO salary percentage | 3.9% |
CEO tenure | 1.8yrs |
CEO ownership | 0.02% |
Management average tenure | 3.8yrs |
Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price
Feb 19Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?
Jan 22Insulet: An Interesting, Yet Expensive, Story
Jan 10Is Insulet (NASDAQ:PODD) Using Too Much Debt?
Jan 09Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors
Dec 27Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Nov 14Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Oct 31We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt
Oct 01Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?
Sep 16Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Aug 14Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger
Jul 31Is Insulet (NASDAQ:PODD) Using Too Much Debt?
Jun 18Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult
May 22Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger
Apr 30Here's Why Insulet (NASDAQ:PODD) Has A Meaningful Debt Burden
Jan 24Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Dec 28Insulet: An Overpriced Play In The Medical Space
Oct 18Insulet (NASDAQ:PODD) Has A Pretty Healthy Balance Sheet
Oct 02Insulet automated insulin delivery system Omnipod 5 gets CE mark
Sep 20The Return Trends At Insulet (NASDAQ:PODD) Look Promising
Sep 05Insulet wins FDA nod to use insulin delivery system in 2 – 5-year-olds
Aug 22Insulet: Bullish Factors For Portfolio Inclusion
Jul 23Insulet to pay $20M to Roche in patent settlement
Jul 11Returns On Capital Are Showing Encouraging Signs At Insulet (NASDAQ:PODD)
Jun 06Is Insulet (NASDAQ:PODD) Using Too Much Debt?
May 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | US$206m |
Sep 30 2023 | n/a | n/a | US$120m |
Jun 30 2023 | n/a | n/a | US$63m |
Mar 31 2023 | n/a | n/a | US$600k |
Dec 31 2022 | US$11m | US$440k | US$5m |
Sep 30 2022 | n/a | n/a | US$17m |
Jun 30 2022 | n/a | n/a | US$35m |
Mar 31 2022 | n/a | n/a | US$45m |
Dec 31 2021 | US$290k | n/a | US$17m |
Sep 30 2021 | n/a | n/a | -US$29m |
Jun 30 2021 | n/a | n/a | -US$30m |
Mar 31 2021 | n/a | n/a | US$9m |
Dec 31 2020 | US$259k | n/a | US$7m |
Sep 30 2020 | n/a | n/a | US$29m |
Jun 30 2020 | n/a | n/a | US$18m |
Mar 31 2020 | n/a | n/a | US$5m |
Dec 31 2019 | US$261k | n/a | US$12m |
Compensation vs Market: Jim's total compensation ($USD11.18M) is about average for companies of similar size in the US market ($USD12.45M).
Compensation vs Earnings: Jim's compensation has increased by more than 20% in the past year.
CEO
Jim Hollingshead (60 yo)
1.8yrs
Tenure
US$11,176,917
Compensation
Dr. James R. Hollingshead, also known as Jim, Ph.D. had been President of Sleep & Respiratory Care Business at ResMed Inc. since July 2020 until May 05, 2022 and served as its President of Sleep Business s...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.8yrs | US$11.18m | 0.020% $ 2.4m | |
Director & Advisor | 1.8yrs | US$16.97m | 0.045% $ 5.4m | |
Executive VP | 6.1yrs | US$2.55m | 0.024% $ 2.9m | |
Group VP | 4.9yrs | no data | 0.0082% $ 965.3k | |
Senior Vice President of Global Operations | 1.2yrs | no data | 0.0077% $ 913.3k | |
Senior VP & CTO | less than a year | no data | 0.023% $ 2.8m | |
Vice President of Investor Relations | 9.2yrs | no data | no data | |
Senior VP & General Counsel | 5yrs | US$2.03m | 0.021% $ 2.5m | |
Senior VP of Regulatory Affairs | 1.3yrs | no data | 0.0044% $ 526.4k | |
Senior Director of Corporate Communications | no data | no data | no data | |
Senior Vice President of Sales & Customer Care | 9.2yrs | no data | no data | |
Senior VP & Chief Human Resources Officer | 3.8yrs | US$1.74m | 0.0062% $ 735.8k |
3.8yrs
Average Tenure
51yo
Average Age
Experienced Management: PODD's management team is considered experienced (3.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.7yrs | US$11.18m | 0.020% $ 2.4m | |
Director & Advisor | 5.5yrs | US$16.97m | 0.045% $ 5.4m | |
Independent Director | 2.1yrs | US$561.51k | 0.0023% $ 274.5k | |
Independent Chairman | 9.6yrs | US$344.09k | 0.036% $ 4.3m | |
Chairman of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Educator Advisory Board | no data | no data | no data | |
Member of Educator Advisory Board | no data | no data | no data | |
Member of Educator Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Educator Advisory Board | no data | no data | no data | |
Independent Director | 5.2yrs | US$298.28k | 0.0074% $ 874.2k |
5.2yrs
Average Tenure
61.5yo
Average Age
Experienced Board: PODD's board of directors are considered experienced (5.2 years average tenure).